ArticleJournal of the American Medical Informatics Association : JAMIA2017
Comparison of three commercial knowledge bases for detection of drug-drug interactions in clinical decision support.
Article in Journal of the American Medical Informatics Association : JAMIA, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- SafeRx: A Canonical Pharmaceutical Knowledge Integration Framework for Multimodal Medication Safety.Bioengineering (Basel, Switzerland) · 2026Article
- Evaluation of dental practitioners' knowledge and attitudes regarding drug interactions: a cross-sectional survey.BMC oral health · 2026Article
- Variability in Drug-Drug Interaction Identification Across Commonly Used Drug Information Resources: An Analysis of Real world Tertiary Care Prescriptions (Retrospective Cross sectional Study).Journal of research in pharmacy practice · 2026Article
- Hypoglycaemia and its associations with diabetes and age-related factors in older home-dwelling people with diabetes.BMC geriatrics · 2025Observational
- Effectiveness of computerised alerts to reduce drug-drug interactions (DDIs) and DDI-related harm in hospitalised patients: a quasi-experimental controlled pre-post study.BMJ quality & safety · 2025Article
- Discrepancies in Recommendations on Pharmacokinetic Drug Interactions for Anticancer Medications and Direct Oral Anticoagulants (DOAC): A Comparative Analysis of Different Clinical Decision Support Systems and Sources.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Pharmacotherapeutic actions related to drug interaction alerts - a questionnaire study among Swedish hospital interns and residents in family medicine.European journal of clinical pharmacology · 2025Article
- Analysis of queries to a Swedish drug information centre identifies scientific knowledge gaps.Scientific reports · 2024Article
- Using electronic health records for clinical pharmacology research: Challenges and considerations.Clinical and translational science · 2024Review
- Major Drug-Drug Interaction Exposure Among Medicaid-Insured Children in the Outpatient Setting.Pediatrics · 2024Article
- Validation and Utility of Drug-Nutrient Interaction and Dietary Supplement Mechanistic Activity in the Natural Medicines Database.JCO oncology advances · 2024Article
- Factors Influencing Health Care Professionals' Perceptions of Frequent Drug-Drug Interaction Alerts.ACI open · 2024Article
- Modeling Precision Feedback Knowledge for Healthcare Professional Learning and Quality Improvement.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2024Article
- Drug-Drug Interactions in Elderly Adults in Dentistry Care: a Cross-Sectional Study.Journal of dentistry (Shiraz, Iran) · 2022Article
- Potential Drug Interactions in Adults Living in Manaus: A Real-World Comparison of Two Databases, 2019.Turkish journal of pharmaceutical sciences · 2022Article
- Similarity and consistency assessment of three major online drug-drug interaction resources.British journal of clinical pharmacology · 2022Article
- Drug interaction alerts in older primary care patients, and related medically justified actions.European journal of clinical pharmacology · 2022Article
- Improving the specificity of drug-drug interaction alerts: Can it be done?American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2022Article
- Drug-Drug-Gene Interactions in Cardiovascular Medicine.Pharmacogenomics and personalized medicine · 2022Review
- Screening for severe drug-drug interactions in patients with multiple sclerosis: A comparison of three drug interaction databases.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo compare 3 commercial knowledge bases (KBs) used for detection and avoidance of potential drug-drug interactions (DDIs) in clinical practice.
methodsDrugs in the DDI tables from First DataBank (FDB), Micromedex, and Multum were mapped to RxNorm. The KBs were compared at the clinical drug, ingredient, and DDI rule levels. The KBs were evaluated against a reference list of highly significant DDIs from the Office of the National Coordinator for Health Information Technology (ONC). The KBs and the ONC list were applied to a prescription data set to simulate their use in clinical decision support.
resultsThe KBs contained 1.6 million (FDB), 4.5 million (Micromedex), and 4.8 million (Multum) clinical drug pairs. Altogether, there were 8.6 million unique pairs, of which 79% were found only in 1 KB and 5% in all 3 KBs. However, there was generally more agreement than disagreement in the severity rankings, especially in the contraindicated category. The KBs covered 99.8-99.9% of the alerts of the ONC list and would have generated 25 (FDB), 145 (Micromedex), and 84 (Multum) alerts per 1000 prescriptions.
conclusionThe commercial KBs differ considerably in size and quantity of alerts generated. There is less variability in severity ranking of DDIs than suggested by previous studies. All KBs provide very good coverage of the ONC list. More work is needed to standardize the editorial policies and evidence for inclusion of DDIs to reduce variation among knowledge sources and improve relevance. Some DDIs considered contraindicated in all 3 KBs might be possible candidates to add to the ONC list.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.